Search results
Gilead's Trodelvy fails bladder cancer trial, modestly extends lung cancer survival
Reuters via Yahoo News· 22 hours ago(Reuters) -Gilead Sciences' Trodelvy failed to improve survival for patients with advanced bladder...
Gilead’s Trodelvy misses goal in bladder cancer study
BioPharma Dive via Yahoo Finance· 23 hours agoTreatment didn’t significantly improve overall survival in the trial, a finding that one analyst...
Gilead's (GILD) Urothelial Cancer Study Did Not Meet Its Primary Goal
Zacks via Yahoo Finance· 17 hours agoGilead Sciences, Inc.'s (GILD) confirmatory TROPiCS-04 study on Trodelvy in locally advanced or...
The Handmaid’s Tale’s Final Season: Everything We Know — Praise Be!
TVLine.com via Yahoo News· 5 days agoBlessed be the fruit… but not for much longer. Hulu’s Emmy-winning dystopian drama The Handmaid’s...
Pharma firm urged to share new 'game-changer' HIV drug
Medical Xpress· 2 days agoMore than 300 politicians, health experts and celebrities on Thursday called for US pharmaceutical...
Welcome Stadium a welcome site for RV thrower Ethan Lyon as the state meet moves from OSU
The Marion Star via Yahoo Sports· 2 days ago...Friday 7:20 p.m. ● Northmor's Ryan Lehman, David Blunk, Griffin Healea, Levi Hunter: D-III boys...
Cell therapy reckoning: How to get cell therapies flying off-the-shelf
FierceBiotech· 21 hours agoThis story is the final part of a four-part series about cell therapy created by the Fierce Biotech...
AstraZeneca-Daiichi's Enhertu follow-up Dato-DXd unable to prove overall survival benefit in phase 3
FierceBiotech· 4 days agoDaiichi Sankyo and antibody-drug conjugate (ADC) partner AstraZeneca have already filed their...
STAMP Inhibitor Tops Imatinib, Second-Gen TKIs for Newly Diagnosed CML
MedPage Today· 1 day agoThe STAMP inhibitor asciminib (Scemblix) had a statistically superior response rate compared with...
Roche’s Sabry retires; Duchenne drug fails confirmatory test
BioPharma Dive via Yahoo Finance· 4 days agoThe veteran executive will be replaced by Boris Zaïtra. Elsewhere, Nippon Shinyaku shared negative...